Group 2 innate lymphoid cells in disease

Timotheus Y. F. Halim

MRC Laboratory of Molecular Biology, Francis Crick Avenue, Cambridge CB2 0QH, UK

Correspondence to: T. Y. F. Halim; E-mail: thalim@mrc-lmb.cam.ac.uk

Received 17 June 2015, accepted 18 August 2015

Abstract

Group 2 innate lymphoid cells (ILC2) are now recognized as an important innate source of type-2 effector cytokines. Although initially associated with mucosal tissues, it is clear that ILC2 are present in diverse anatomical locations. The function of ILC2 at these sites is equally varied, and although ILC2 represent a relatively minor population, they are fundamentally important regulators of innate and adaptive immune processes. As such, there is much interest to understand the role of ILC2 in diseases with a type-2 inflammatory component. This review explores the known roles of ILC2 in disease, and the diseases that show associations or other strong evidence for the involvement of ILC2.

Keywords: allergies, ILC2, innate immunity, type-2 inflammation

Introduction

Group 2 innate lymphoid cells (ILC2) are key mediators of type-2 immune responses and comprise a potent cellular source of the canonical type-2 effector cytokines IL-5 and IL-13 (reviewed in (1)). ILC2 were initially noted as non-T-non-B cells that shared similar effector functions as CD4+ T helper 2 (Th2) cells (2–4). Given their low cell numbers compared with CD4+ T cells in most tissues of naive animals, and the absence of a known lineage-specific cell surface marker, ILC2 continued to fly under the radar until being characterized independently by several groups in 2010 (5–7). These, and subsequent, studies established that ILC2 comprise a distinct lineage of innate lymphocytes that, independently of Th2 cells, can mount potent type-2 immune responses (1, 8).

Importantly, ILC2 are not activated by direct interactions with antigens though a T-cell receptor (TCR) or a BCR, or by antibody-mediated activation. Furthermore, ILC2 are not known to express pathogen-associated molecular pattern receptors. Instead, in addition to the common γ-chain (CD132; a subunit of the heteromeric receptors for e.g. IL-2, IL-4, IL-7 and IL-9), ILC2 express CD25 (another IL-2 receptor subunit) and CD127 (the other IL-7 receptor subunit), as well as receptors for cytokines that are rapidly released by damaged or stimulated epithelial cells including ST2 (an IL-33 receptor subunit), IL-17RB (a receptor subunit e.g. IL-25) and TSLPR (which, along with CD127, comprises the receptor for thymic stromal lymphopoietin) (1). Thus, tissue-resident ILC2 act as sentinels and translate epithelium-derived signals into an amplified innate type-2 response. In the gut, this response is critical for anti-helminth immunity, where ILC2-derived IL-5 and IL-13 potentiate eosinophilic inflammation, goblet cell hyperplasia and mucus secretion.

Following their discovery in gut-associated tissues, it has become evident that ILC2 may be involved in other innate type-2 immune processes. To date, ILC2 have been implicated or associated with an increasing list of diseases (Table 1). Importantly, ILC2 also function in other type-2 cytokine-driven processes such as lipid metabolism and thermogenesis in adipose tissue (9–12), eosinophil homeostasis (13, 14) and the development of alternatively activated macrophages (13). Furthermore, innate IL-5-producing cells are present in the uterus, heart, kidney and brain of naive mice (14), suggesting potential roles of ILC2 in these organs.

This review addresses the known or hypothesized roles, and mechanisms of ILC2 in disease processes, broadly divided by organ system. This is preceded by an overview of the regulation of ILC2 function.

Regulation and function

ILC2 are part of a larger ID2-transcription-factor-dependent innate lymphoid cell (ILC) family, which also includes ILC1, ILC3 and NK cells (8). ILC2 differentiate from a common ILC precursor found in the bone marrow (15, 16) via immature ILC2 (17, 18). The transcription factors RORγt (18, 19), GFI-1 (20), GATA3 (17, 21), TCF1 (22) and Bcl11b (23, 24) are essential for ILC2 development and function. Notably, GATA3 is also required for ILC3 differentiation (25).

The upstream type-2-associated cytokines IL-33, IL-25 and TSLP are collectively essential for ILC2 activation but individually have different importance depending on factors such as tissue location (1, 26). Nevertheless, other soluble and cell-to-cell signals also contribute to ILC2 regulation (Figs 1 and 2), and our understanding of their function in the context of the overall immune response remains incomplete.
Using models of ILC2-specific depletion or deficiency, it is becoming clear that ILC2 can instruct the adaptive immune response (e.g. see Fig. 3) (27–31). ILC2-derived IL-13 is necessary for efficient trafficking of dendritic cells (DC) to the draining lymph node during allergic lung inflammation, thus indirectly influencing Th2 cell priming (29). ILC2 can also express MHC class II, OX40L, CD80 and CD86, and can directly activate CD4+ T cells (27, 28, 31). Conversely, activated CD4+ T-cell-derived IL-2 can synergize with IL-33 to stimulate ILC2 (27, 28). In addition to T cells, ILC3 are also a potential source of IL-2 as suggested by Il2 fate reporter analysis (32). Moreover, IL-2 is required for IL-33-mediated activation of ILC (46). In addition, nutritional status also likely influences ILC2 biology, as vitamins A and D are known to skew the ILC3/ILC2 balance in the intestines (47, 48). Thus, it is clear that ILC2 are tightly regulated by their environment and function as a potent inducer of innate and adaptive immune processes.

### ILC2 in diseases of the gastrointestinal tract

#### Helminth infection

Type-2 immunity is essential for anti-helminth responses, involving both innate and adaptive immune processes (49). ILC2 were first identified in the intestine, mesenteric lymph nodes and fat-associated lymphoid clusters (FALC) as a lineage–CD127+CD25+ST2+IL-17RB+ innate lymphoid population that required IL-25 and/or IL-33 signaling for activation in response to Nippostrongylus brasiliensis (Nb) infection (5–7). ILC2 are a critical innate source of IL-13 that is important...
for efficient helminth expulsion in the absence of adaptive immunity. In sensitized animals, both ILC2 and T_{h2} cells cooperate to eliminate Nb-larvae in the lungs upon re-infection, preventing their maturation and trafficking to the stomach and intestines (50). Furthermore, ILC2-derived IL-9, acting via autocrine and paracrine mechanisms, is critical for epithelial repair and efficient helminth expulsion following Nb infection (34). Besides inducing inflammation, ILC2 are also an important cellular source of amphiregulin (51), a growth factor critical in wound repair processes and anti-helminth immunity (49). Moreover, ILC2 appear to be the major source of amphiregulin following Nb infection (34).

Human lineage CD127^{+}CD161^{+}CRTH2^{+}ST2^{+} ILC2 were identified in embryonic intestinal tissue (52). Although human
and murine ILC2 are similarly regulated, little is known about the role of human ILC2 in parasite infection as of yet. Although one study reported increased blood ILC in patients infected with filarial worms (53), more recently blood ILC2 proportions were found to be reduced during Schistosome infection (54).

As circulating ILC2 numbers do not accurately reflect activation and expansion in affected tissues (7), further studies are needed to reveal the role of ILC2 in human helminthiasis.

Colitis

Although ILC3 are essential for intestinal homeostasis, and both ILC1 and ILC3 have been implicated in inflammatory bowel diseases, the role of ILC2 in these processes remains uncertain (55). To date, IL-13 is known to mediate colitis after oxazolone treatment, partially driven by IL-25-dependent activation of ILC2 (56). Crohn’s disease patients also have increased numbers of intestinal IL-13+ ILC, suggesting a possible role for ILC2 in pathogenesis (57).

Other diseases

The potential function of ILC2 in other diseases of the gastrointestinal (GI) tract is of keen interest. FALC-resident ILC2 can interact with IgA-secreting B-1 cells, which are essential for the clearance of GI pathogens (5). Recently, a model of *Bacillus anthracis* infection in mice reported a concomitant reduction in B-1 cells and ILC2 and impairment in ILC2 function compared with uninfected animals (58). Furthermore, IL-33, IL-25 and TSLP have been linked with food allergies (59–61) and eosinophilic esophagitis (62). Nevertheless, it is important to recognize the contribution of other innate immune cells such as eosinophils, basophils and mast cells, which are also known to respond to epithelium-derived cytokines and mediate type-2 inflammation. It is likely that the relative contributions of different cells in inflammatory processes are highly tissue dependent.

ILC2 in diseases of the airways

Allergic lung disease

Type-2 immunity plays a central role in allergic lung disease (63). Furthermore, genome-wide association studies of asthmatic patients have identified numerous components of the type-2 inflammatory process, including ILC2-associated genes such as *RORA*, *IL33*, *IL1RL1* (which encodes ST2) and *IL13* (64). In mice, ILC2 are found in naive lungs, where they are critical for mounting an innate type-2 response to inhaled allergens (65) and are the primary source of IL-5 and IL-13 in response to allergen-induced release of IL-33, TSLP or IL-25 (65–67). Although these three cytokines all influence ILC2 activation, purified naive lung ILC2 require IL-33 for type-2 cytokine production (65). Similar regulatory requirements are noted in human ILC2 (38, 52). Likewise, IL-33 is a more potent inducer of ILC2 than IL-25 is, in ragweed-challenged mice or mice challenged with *Alternaria alternata* allergen (68).

Multiple other studies indicate that IL-33 is a key activator of lung ILC2 in the context of innate type-2 lung inflammation (69–71). IL-25, in contrast, appears to play a more
ILC2 in disease

prominent role in gut ILC2 activation (6), which coincides with reduced ST2 expression on enteric ILC2 (18). Interestingly, intranasal administration of recombinant IL-25 promotes the early emergence of an IL-17RB*KLRG1* population in the lung (72), which, like enteric ILC2, are ST2- and CD127low. However, IL-25-elicited KLRG1* lung ILC2 may convert into ST2+ ILC2, suggesting that the tissue-specific microenvironment may strongly influence ILC2 regulation.

ILC2 are a potent innate source of type-2 cytokines in allergic lung inflammation. Naive lung ILC2 are primed to secrete IL-5, as indicated by elevated Il5 transcript (65) and constitutive Il5-reporter expression (14). ILC2-derived IL-5 is important for eosinophilic homeostasis, whereas the local production of IL-13 and the eosinophil-recruiting chemokine eotaxin is essential for eosinophilic lung inflammation following allergen exposure (14). ILC2 are the major source of IL-13 during acute allergic inflammation, which induces goblet-cell hyperplasia, mucus overproduction and smooth-muscle contraction, all of which adversely affect airflow and lung function (73). In addition, ILC2 play a significant role in promoting airway hyper-reactivity, mediated by IL-25, IL-33 and ICOS signaling (37, 68, 74–76). In addition, ILC2-derived IL-13 promotes lymph-node trafficking of lung DC in a pro-allergen-allergen model of lung inflammation, thus linking the innate type-2 response to allergen-sensitization of T* cells (29). Using Rora–/– bone-marrow-transplanted mice, which lack ILC2 but can generate normal T* cells, it was shown that inhaled allergens failed to induce efficient T* cell priming, resulting in diminished IgE production and diminished type-2 inflammation (18, 29, 30).

ILC2 are also a critical early source of IL-9 in allergen-induced airway inflammation (33). Besides autocrine regulation of ILC2 survival, IL-9 supports goblet-cell hyperplasia and mast-cell proliferation in the lungs of helminth-infected mice, suggesting an analogous function in atopic airway disease (34, 77). Mast cells were observed in proximity to lung CD117*CD161+ ILC2 in healthy subjects and can enhance ILC2 activation directly via the production of PGD2 or perhaps indirectly by releasing proteases that cleave IL-33 into a more bioactive isoform (78). Moreover, mast cells are also a direct source of IL-33 upon antigen-specific IgE-mediated activation (79).

The relative contribution of ILC2 versus T* cells toward pathology after allergen re-exposure in a sensitized host is an important question when considering the potential impact of ILC2-targeted therapies. Several reports have shown that the magnitude of ILC2-mediated inflammation is contingent on the adaptive immune system (6, 29, 50, 80). Rag2+/– mice (which are deficient in T and B cells) can mount an ILC2-driven type-2 response to allergen but, unlike wild-type mice, do not generate an amplified immune reaction after re-challenge with the same allergen (29). Upon allergen re-challenge in primed wild-type mice, T* cells comprise an important cellular source of type-2 cytokines, consistent with immune memory and T* cell differentiation.

Nevertheless, type-2-cytokine-producing ILC2 also expand greatly in number after re-challenge with a protease allergen (papain)-sensitized animals or after repeated challenges with house dust mite (HDM) extract (29, 67). Moreover, ILC2 performed an important, but secondary, role to T* cells, in mediating the recall response to inhaled ovalbumin antigen (80). However, another study suggests that ILC2 play a more prominent role in an HDM model of chronic asthma (81). Nevertheless, these studies suggest collaboration between ILC2 and T* cells as producers of effector type-2 cytokines in the context of allergic airway inflammation.

To date, ILC2 have been identified in the lungs of human fetal tissue, and in the bronchoalveolar lavage and lungs of healthy subjects (51, 52). Subsequently, it was reported that asthma patients have more circulating ILC2 (82). Conversely, others have observed similar numbers of circulating ILC2 in severe or mild asthma patients and healthy subjects but instead noted reduced NK cells in the blood of asthma patients (41). Interestingly, this study also shows that ILC2 activation can be dampened by lipoxin A4, a pro-resolvin molecule that binds to ALX/FPR2 receptors expressed on ILC2. Another study demonstrated that corticosteroids, commonly used to treat asthma, inhibit murine ILC2 activation by IL-33 (83). The same study also shows that TSLP counters the effect of corticosteroids on ILC2. Clearly, further translational work is needed to establish the role of lung ILC2 in humans.

Alternatively, ILC2 are hypothesized to play a role in asthma exacerbations. The hypothesis that susceptible individuals (perhaps because of elevated production of alarmins such as IL-33, elevated numbers of ILC2 or an elevated propensity for ILC2 stimulation) may be more prone to ILC2 activation is attractive because of their relatively indiscriminant activation by alarmin release upon cellular damage or stress (1). In support of this, mice with allergic lung inflammation had increased numbers of IL-33-producing type-2 pneumocytes, which may imply a higher potential for ILC2 activation (84). TSLP is also mainly produced by type-2 pneumocytes in response to chitin or helminth exposure (85). Moreover, it is clear that ILC2 are activated upon influenza infection in an IL-33-dependent manner (51, 52, 86). Influenza and also rhinovirus infections are known to cause asthma exacerbations in humans (63, 87). Indeed, IL-33 and IL-25 are induced upon rhinovirus infection, and type-2 effector cytokines are elevated in infected asthmatic patients, thus suggesting a possible role for ILC2 (88, 89).

Asthma exacerbations can also occur after exposure to fungal antigens. In mice, intranasal Alternaria alternata exposure caused IL-33-dependent exacerbated disease in animals sensitized with an alternative antigen (90). Overall, it appears that ILC2 are activated in response to a wide range of stimuli.

Rhinosinusitis

Type-2 inflammation is associated with chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), an endotype of CRS that can be further subdivided based on eosinophilic infiltration (91). CRSwNP affects the nose and paranasal sinuses, with clinical symptoms including nasal congestion/obstruction and fatigue. Initially, ILC2 enrichment was demonstrated in the polyps of CRS patients (52). These and subsequent data from the same group showed that nasal polyp ILC2 are a potent source of type-2 cytokines in response to IL-33, IL-25 and TSLP (21). The association between ILC2 and CRSwNP was further demonstrated in a number of subsequent studies.
(92–95). Additional correlations were found between elevated poly ILC2 numbers and increased local and circulating eosinophil numbers (92, 95). Allergic rhinitis, which over time can develop into CRS, is also associated with ILC2, as suggested by increased circulating ILC2 after allergen challenge in sensitized patients (96). Moreover, nasal-mucosal ILC2 from CRSwNP patients produced IL-13 when stimulated with IL-33, and IL33 transcript was elevated in nasal epithelium after exposure to fungal allergen (94). Interestingly, corticosteroid treatment of CRSwNP patients led to a reduction in ILC2 number (95). The same study also showed that corticosteroids induced apoptosis of lung ILC2 in mice. Therefore, it is evident that ILC2 are present in the nasal mucosa and are likely associated with type-2 inflammation in CRSwNP.

Lung infections

Lung ILC2 were first identified in influenza models of lung inflammation (51, 75). Importantly, Monticelli et al. (51) reported that ILC2 play a central role in tissue repair following infection by their production of amphiregulin. Moreover, the cellular source of IL-33 may be different during viral infections and allergic inflammation. In addition to epithelial cells, alveolar macrophages and invariant NK T cells were reported as potential sources of IL-33 in influenza-infected lungs (75, 86).

Furthermore, a recent study found that cigarette smoke enhanced epithelial IL-33 production while also altering the expression of its receptor, ST2, on the surface of ILC2 and other immune cells (97). Interestingly, cigarette smoke exposure resulted in a dampened ILC2 response and an exacerbated type-1 response upon influenza infection, thus proposing another protective role of ILC2 in the lung. However, although ILC2 may be beneficially involved in the wound-healing response, the dysregulation of this pathway can lead to fibrosis. ILC2-derived IL-13 is responsible for collagen deposition in the lungs of mice treated with Schistosoma mansoni eggs (98). In another study, bleomycin-induced lung fibrosis was found to be mediated in part by IL-33 (99).

Thus, it appears that ILC2 are a piece in a complex puzzle of the lung immune system and have roles in multiple seemingly unrelated immune processes. Recently, the influence of infections, microbiota and allergen exposures on the postnatal development of the immune system has been investigated. Early-life viral infections have been associated with the development of asthma. In mice, rhinovirus infection of neonates elicits amplified ILC2 activation compared with adult mice (74), although this may be due to reduced lung Treg cells, whose emergence after birth is dependent on microbial colonization of the lung (100). Further studies are required to delineate the role of ILC2 on the lung immune system in health and disease.

ILC2 in diseases of the skin

Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by increased concentrations of type-2 cytokines in skin lesions. Furthermore, samples of AD lesions exhibit higher expression of IL1RL1 (ST2), AREG, IL17RB, TSLPR and RORA compared with healthy subjects, suggesting an enrichment of ILC2 in disease (38).

Skin-resident ILC2 were first characterized in mice as lineage-εCD25εCD127εCD90εICOSε cells (101) and were subsequently also distinguished from ILC2 in other anatomical sites by their expression of CD103, an integrin expressed by other skin-resident leukocytes (102).

While relatively abundant during homeostasis, skin ILC2 numbers expanded after administration of a topical vitamin D analog (calcipotriol), allergen (HDM) or in response to IL-2 signaling (38, 101, 102). Kim et al. (101) reported that skin ILC2 activation is critically dependent on TSLP signaling. More recently, mice with skin-specific overexpression of IL-33 were shown to develop spontaneous dermatitis with increased ILC2 numbers (103). Therefore, although skin ILC2 can respond to IL-25, IL-33 and TSLP as shown by impaired calcipotriol-induced skin inflammation in mice with knockouts of individual receptors (38), it remains unclear if one of these cytokines plays a more prominent role in AD. Nevertheless, using ILC-deficient Rora-/- bone-marrow-transplanted mice, or by antibody-mediated ILC2 depletion, it is clear that ILC2 are critical mediators of the acute type-2 inflammatory response in the skin (38, 101).

Human skin ILC2 were identified as lineage-ε cells, which expressed CD127, CRTH2, ST2, CD161, CD25, ICOS and c-Kit. Whereas skin ILC2 were present in healthy subjects, their numbers were elevated in lesional biopsies or blood samples taken from AD patients (38, 101). Furthermore, human skin ILC2 activation was suppressed by E-cadherin binding to KLRG1 expressed on the surface of activated ILC2 (38). Thus, human ILC2 are present in the skin during homeostasis and are a potent innate source of type-2 cytokines upon stimulation. As mouse studies also show that the adaptive immune system is necessary for efficient ILC2 responses in the skin (101), it is possible that AD in humans involves both T cells and ILC2. Interestingly, basophil-derived IL-4 can enhance ILC2 function and mast cells are found in proximity to skin ILC2, hinting at possible interactions between these cells (35, 102). Taken together, ILC2 appear to play a prominent role in driving skin type-2 inflammation; however, further work is needed to elucidate the exact role and regulation of ILC2 in the skin.

ILC2 in other anatomical sites

Although ILC2 have a distinct role at anatomical barrier sites, it is becoming clear that they are present in numerous other tissues. Indeed, many diseases driven by type-2 inflammation, or its upstream cytokines such as IL-33, IL-25 and TSLP, may involve ILC2. Liver fibrosis is associated with increased serum IL-33, and it has now been shown that hepatic ILC2 are important for IL-33-driven IL-13 production (104, 105). IL-13 in turn induces cholangiocyte hyperplasia and hepatic stellate-cell activation, which are associated with biliary atresia and hepatic fibrosis, respectively (104, 105). However, these processes likely also serve a protective role as demonstrated by the increased susceptibility to virus-induced tissue damage when this pathway is blocked (104). Indeed, IL-33 is also increased in models of viral hepatitis, and activated hepatic ILC2 may also modulate the inflammatory response as indicated by their ability to limit cytokine production from macrophages and T cells (106).
ILC2 have also been identified in the brain and are implicated in polarizing the immune environment in cerebral malaria (107). Mice infected with Plasmodium spp. benefitted from adoptively transferred ILC2, although other IL-33 responsive cells including T$_{reg}$ cells also contributed to the protection against experimental cerebral malaria. ILC2 in the nervous system may also play a role in multiple sclerosis. ILC2 were found to accumulate in the brain and draining lymph nodes of mice that were resistant to experimental autoimmune encephalitis (EAE) (108). The authors hypothesize that ILC2 skew the immune environment toward a protective T$_{reg}$-dominated response. This argument is supported by increased disease in ST2$^-$ animals; and IL-33 administration is protective in EAE (109–111).

ILC2 are also reported in the aorta, where they are hypothesized to interact with B-1a cells and help regulate production of natural IgM antibody to low-density lipoprotein, which protects against atherosclerosis (112). Moreover, IL-25 administration has been shown to reduce atherosclerosis in mice, possibly through interactions between ILC2 and B-1 cells (113).

Not much is known about the role of ILC2 in cancer, although Li et al. (105) report that IL-33 facilitates biliary carcinogenesis. Furthermore, it is uncertain if some leukemias can arise from ILC2. Nevertheless, it is becoming clear that many of our current treatments influence the biology of ILC2. Severe epithelial damage caused by graft-versus-host disease (GVHD) in allogeneic hematopoietic stem-cell-transplanted (HSCT) patients may influence, or be influenced by, ILC2. A recent study indicated that ILC (including ILC2) reconstitution after HSCT was slow compared with other blood lineages and that more rapid recovery of the ILC compartment coincided with reduced GVHD (114).

Another form of immunotherapy involves treatment with IL-2, which has been approved for some forms of cancer and as anti-autoimmune therapy, but has numerous side effects including eosinophilia. We now understand that IL-2 is a potent in vivo activator of ILC2 (27, 32, 102), which a recent study indicates that it promotes eosinophilia via ILC2-derived IL-5 (115). As illustrated by the discovery of ILC2 in numerous non-barrier tissues, it is important to consider their function in an increasing number of organs and diseases.

**Conclusion**

It appears that ILC2 have a more complex role in health and disease than originally envisioned. Although initially perceived as a remnant of the innate immune system, holding the fort until the adaptive immune system comes to the rescue, it is increasingly evident that ILC2 may be a critical component in many disease, and homeostatic, processes. A body of evidence suggests that ILC2 function is tightly controlled by the microenvironment, and therefore, it is likely that ILC2 act in a tissue-specific manner. On this, we layer the plasticity of the immune response, which underscores the importance of delineating the function and regulation of ILC2 throughout the immune response in order to devise effective therapeutic strategies.

More specifically, further studies are needed that dissect the regulation of ILC2 by the increasingly diverse activation and/or inhibitory signals. Moreover, it is important to understand the kinetics of ILC2 responses, and their development or recruitment into inflamed tissues. In relation to this aim, more research is needed into ILC2 development in the bone marrow, or maturation in the periphery, which may identify more ILC2-restricted targetable molecules. Already ROR$\alpha$ is known to be essential for efficient ILC2 development specifically, although recent studies show its expression in other ILC lineages too. Nevertheless, mutant Rora$^{sg/sg}$ bone-marrow-transplanted mice appear to have relatively normal ILC3 numbers. The use of ROR$\alpha$ small-molecule antagonists or agonists should be evaluated, although it is important to consider that ROR$\alpha$ function is also essential for neuronal development, which may inhibit its usefulness as a drug target. However, already there are many targeted therapies that may (amongst effects on other immune cells) influence ILC2 in various stages of development or clinical use (reviewed in (116)). Lastly, it is important to translate our understanding of mouse ILC2 biology to the human system. Although this is difficult, novel tools such as the humanized immune system mouse, xenotransplants or human-tissue explant cultures may provide answers.

**Funding**

Canadian Institutes of Health Research—Banting Postdoctoral Fellowship (to T.Y.F.H.).

**Acknowledgements**

We thank S. Scanlon for critical reading.

**Conflict of interest statement:** The author declared no conflict of interests.

**References**


36 Motomura, Y., Morita, H., Moro, K. et al. 2014. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 40:758.


44 Yu, X., Pappu, R., Ramirez-Carrozzi, V. et al. 2014. TNF superfamily member TL1A elicits type 2 innate lymphoid cells at mucosal barriers. Mucosal Immunol. 7:730.


58 Barlow, J. L., Peel, S., Fox, J. et al. 2013. IL-33 is more potent than IL-25 in provoking IL-13-producing nuocytes (type 2 innate lymphoid cells) and airway contraction. J. Allergy Clin. Immunol. 132:933.


Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection. *Immunity* 42:566.


